ATE548353T1 - Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon. - Google Patents

Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon.

Info

Publication number
ATE548353T1
ATE548353T1 AT04757266T AT04757266T ATE548353T1 AT E548353 T1 ATE548353 T1 AT E548353T1 AT 04757266 T AT04757266 T AT 04757266T AT 04757266 T AT04757266 T AT 04757266T AT E548353 T1 ATE548353 T1 AT E548353T1
Authority
AT
Austria
Prior art keywords
ureas
phenylü
pyrazole
aryl
producing substituted
Prior art date
Application number
AT04757266T
Other languages
English (en)
Inventor
John Robert Fritch
Fiona M Carleton
Edward A Lally
Hongmei Li
Bradley Teegarden
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Application granted granted Critical
Publication of ATE548353T1 publication Critical patent/ATE548353T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AT04757266T 2004-03-23 2004-07-21 Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon. ATE548353T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55562604P 2004-03-23 2004-03-23
PCT/US2004/023880 WO2005103011A1 (en) 2004-03-23 2004-07-21 Processes for preparing substituted n-aryl-n’-[3-(1h-pyrazol-5-yl) phenyl] ureas and intermediates thereof

Publications (1)

Publication Number Publication Date
ATE548353T1 true ATE548353T1 (de) 2012-03-15

Family

ID=34958223

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04757266T ATE548353T1 (de) 2004-03-23 2004-07-21 Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon.

Country Status (7)

Country Link
US (1) US7812176B2 (de)
EP (1) EP1727803B3 (de)
CN (1) CN1926114B (de)
AT (1) ATE548353T1 (de)
CA (1) CA2559038C (de)
HK (1) HK1092152A1 (de)
WO (1) WO2005103011A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20060035A (en) 2003-07-22 2008-08-07 Arena Pharmaceuticals Inc., Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
EP1727803B3 (de) 2004-03-23 2014-04-23 Arena Pharmaceuticals, Inc. Verfahren zur herstellung von substituierte n-aryl-n'-[3-(1h-pyrazol-5-yl)phenyl]-harnstoffe and intermediate davon.
SA05260357B1 (ar) 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
AR052886A1 (es) * 2005-01-26 2007-04-11 Arena Pharm Inc Procedimientos para preparar fenilpirazol ureas sustituidas y para la obtencion de sus intermediarios de sintesis
CN104761498B (zh) 2006-05-18 2017-12-26 艾尼纳制药公司 5‑ht2a血清素受体的调节剂
ES2536762T3 (es) 2006-05-18 2015-05-28 Arena Pharmaceuticals, Inc. Aminas primarias y sus derivados como moduladores del receptor de la serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con este
NZ571829A (en) 2006-05-18 2011-10-28 Arena Pharm Inc Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ, インコーポレイテッド 5−HT2Aセロトニン受容体に関連した障害の治療のための5−HT2Aセロトニン受容体のモジュレーターとしてのイミダゾ[1,2−a]ピリジン誘導体
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
RS57110B1 (sr) 2008-10-28 2018-06-29 Arena Pharm Inc Sastavi modulatora 5-ht2a serotoninskog receptora korisni za tretiranje poremećaja povezanih sa njim
US9126946B2 (en) * 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
WO2011075596A1 (en) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
EP2855477A4 (de) * 2012-05-29 2015-11-18 Merck Sharp & Dohme Isotopisch markierte biaryl-harnstoffverbindungen
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
CN109562085A (zh) 2015-06-12 2019-04-02 阿速万科学有限责任公司 用于预防和治疗rem睡眠行为障碍的二芳基和芳基杂芳基脲衍生物
AU2016291673A1 (en) 2015-07-15 2018-01-25 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
KR20220045189A (ko) 2019-08-12 2022-04-12 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양을 치료하는 방법
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
JP2023509628A (ja) 2019-12-30 2023-03-09 デシフェラ・ファーマシューティカルズ,エルエルシー 1-(4-ブロモ-5-(1-エチル-7-(メチルアミノ)-2-オキソ-1,2-ジヒドロ-1,6-ナフチリジン-3-イル)-2-フルオロフェニル)-3-フェニル尿素の組成物
EP4327827A3 (de) 2019-12-30 2024-05-29 Deciphera Pharmaceuticals, LLC Amorphe kinasehemmerformulierungen und verfahren zur verwendung davon
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1643310A1 (de) 1966-12-29 1971-06-03 Dow Chemical Co 4-Alkyl-2,5-dimethoxy-alpha-methyl-phenaethylamin und seine pharmakologisch vertraeglichen Salze
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
DE2926517A1 (de) * 1979-06-30 1981-01-15 Beiersdorf Ag Substituierte 3-aryl-pyrazole und 5-aryl-isoxazole und verfahren zu ihrer herstellung
DE2928485A1 (de) 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
US4985352A (en) 1988-02-29 1991-01-15 The Trustees Of Columbia University In The City Of New York DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof
US5661024A (en) 1989-10-31 1997-08-26 Synaptic Pharmaceutical Corporation DNA encoding a human serotonic (5-HT2) receptor and uses thereof
US5077409A (en) 1990-05-04 1991-12-31 American Cyanamid Company Method of preparing bis-aryl amide and urea antagonists of platelet activating factor
US5128351A (en) 1990-05-04 1992-07-07 American Cyanamid Company Bis-aryl amide and urea antagonists of platelet activating factor
FR2682379B1 (fr) 1991-10-09 1994-02-11 Rhone Poulenc Agrochimie Nouveaux phenylpyrazoles fongicides.
FR2690440B1 (fr) 1992-04-27 1995-05-19 Rhone Poulenc Agrochimie Arylpyrazoles fongicides.
DE69411176T2 (de) 1993-08-20 1998-11-12 Smithkline Beecham Plc Amide und harnstoffderivate als 5ht1d rezeptor antagonisten
FR2722369B1 (fr) * 1994-07-13 1998-07-10 Rhone Poulenc Agrochimie Compositions fongicides a base de derives 3-phenyl-pyrazoles pour le traitement du materiel vegetal de multiplication, nouveaux derives 3-phenyl-pyrazoles et leurs applications fongicides
WO1996010559A1 (en) 1994-10-04 1996-04-11 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
CA2135253A1 (en) 1994-11-07 1996-05-08 Michael Dennis Compound screening based on a window of chemical-messenger-independent activity
JPH10513442A (ja) 1995-02-02 1998-12-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5−htレセプターアンタゴニストとしてのインドール誘導体
WO1996025157A1 (en) 1995-02-17 1996-08-22 Smithkline Beecham Corporation Il-8 receptor antagonists
AU6526896A (en) 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US6005008A (en) 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
GB9607219D0 (en) 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
JP2000510862A (ja) 1996-05-24 2000-08-22 ニューロサーチ・アクティーゼルスカブ クロライドチャンネル遮断剤として有用なフエニル誘導体
WO1997045400A1 (en) 1996-05-24 1997-12-04 Neurosearch A/S Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers
EP0915651A4 (de) 1996-06-27 2001-10-24 Smithkline Beecham Corp Il-8 rezeptor-antagonisten
WO1998024785A1 (en) 1996-12-02 1998-06-11 Fujisawa Pharmaceutical Co., Ltd. Indole-urea derivatives with 5-ht antagonist properties
US6420541B1 (en) 1998-04-14 2002-07-16 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
US6541209B1 (en) 1997-04-14 2003-04-01 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
BR9808938A (pt) 1997-04-22 2000-08-01 Neurosearch As Composto, composição farmacêutica, uso de um composto, processos para o tratamento de um distúrbio ou doença de um corpo de animal vivo e para a preparação de um composto, e, uso de bloqueadores de canal de cloreto
US6696475B2 (en) 1997-04-22 2004-02-24 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
AU8673198A (en) 1997-07-29 1999-02-22 Smithkline Beecham Corporation Il-8 receptor antagonists
SK5462000A3 (en) 1997-10-31 2001-02-12 Aventis Pharma Ltd Substituted anilides
JPH11183942A (ja) 1997-12-19 1999-07-09 Nippon Mitsubishi Oil Corp エレクトロクロミック素子
DE1042305T1 (de) 1997-12-22 2001-04-19 Bayer Ag HEMMUNG DER p38 KINASE UNTER VERWENDUNG VON SYMMETRISCHEN UND ASYMMETRISCHEN DIPHENYLHARNSTOFFEN
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
CN1213022C (zh) 1997-12-22 2005-08-03 拜尔有限公司 用对称和不对称的取代二苯脲抑制raf激酶
ES2156845T1 (es) 1998-04-14 2001-08-01 Arena Pharm Inc Receptores de serotonina humana no endogenos constitutivamente activados y moduladores de moleculas pequeñas para estos.
US6140509A (en) * 1998-06-26 2000-10-31 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof
GB9816263D0 (en) 1998-07-24 1998-09-23 Merck Sharp & Dohme Therapeutic agents
US6358698B1 (en) 1998-10-07 2002-03-19 Acadia Pharmacueticals Inc. Methods of identifying inverse agonists of the serotonin 2A receptor
ATE286021T1 (de) 1998-10-22 2005-01-15 Neurosearch As Substituierte phenylderivate, ihre herstellung und verwendung
US6150393A (en) 1998-12-18 2000-11-21 Arena Pharmaceuticals, Inc. Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors
AR023171A1 (es) 1999-03-26 2002-09-04 Cocensys Inc Pirazoles, imidazoles, oxazoles, tiazoles, y pirroles sustituidos por arilo, y el uso de los mismos.
GB9909409D0 (en) 1999-04-24 1999-06-23 Zeneca Ltd Chemical compounds
WO2001021160A2 (en) 1999-09-23 2001-03-29 Axxima Pharmaceuticals Aktiengesellschaft Carboxymide and aniline derivatives as selective inhibitors of pathogens
US6531291B1 (en) 1999-11-10 2003-03-11 The Trustees Of Columbia University In The City Of New York Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof
EP1108720A1 (de) 1999-12-08 2001-06-20 Basf Aktiengesellschaft Herbizide 2-Pyrazolyl-6-Aryloxy-Pyri(mi)dine
FR2810979B1 (fr) 2000-06-29 2002-08-23 Adir Nouveaux derives de diphenyluree, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2002039987A2 (en) 2000-11-14 2002-05-23 Neurosearch A/S Use of malaria parasite anion channel blockers for treating malaria
AR035521A1 (es) 2000-12-22 2004-06-02 Lundbeck & Co As H Derivados de 3-indolina y composicion farmaceutica que los comprende
US20020156068A1 (en) 2001-03-22 2002-10-24 Behan Dominic P. Anti-psychosis combination
CH1427415H1 (de) 2001-09-21 2023-12-21 Bristol Myers Squibb Holdings Ireland Lactamhaltige verbindungen und ihre derivate als faktor-xa-hemmer
WO2003062206A2 (en) 2002-01-23 2003-07-31 Arena Pharmaceuticals, Inc. Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
AU2003275093A1 (en) 2002-09-24 2004-04-19 Arena Pharmaceuticals, Inc. Process of making phenylpyrazoles useful as selective 5ht2a modulators and intermediates thereof
TWI258934B (en) 2002-11-08 2006-07-21 Interdigital Tech Corp Composite channel quality estimation techniques and systems for wireless receivers
WO2004058722A1 (en) 2002-12-24 2004-07-15 Arena Pharmaceuticals, Inc. Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
WO2004071426A2 (en) 2003-02-11 2004-08-26 Kemia Inc. Compounds for the treatment of viral infection
EP1611128A2 (de) 2003-03-28 2006-01-04 Pharmacia & Upjohn Company LLC Positive allosterische modulatoren des nikotinischen acetylcholin-rezeptors
GB0309781D0 (en) 2003-04-29 2003-06-04 Glaxo Group Ltd Compounds
RS20060035A (en) 2003-07-22 2008-08-07 Arena Pharmaceuticals Inc., Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
US7368593B1 (en) * 2003-08-18 2008-05-06 Organics L.L.C. Method of selective esterification
US20050054691A1 (en) 2003-08-29 2005-03-10 St. Jude Children's Research Hospital Carboxylesterase inhibitors
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
EP1727803B3 (de) 2004-03-23 2014-04-23 Arena Pharmaceuticals, Inc. Verfahren zur herstellung von substituierte n-aryl-n'-[3-(1h-pyrazol-5-yl)phenyl]-harnstoffe and intermediate davon.
WO2006004722A2 (en) 2004-06-30 2006-01-12 Biomol Research Laboratories, Inc. Compositions and methods for selectively activating human sirtuins
US20080261952A1 (en) 2004-08-16 2008-10-23 Jason Bloxham Aryl Urea Derivatives for Treating Obesity
US20060063754A1 (en) 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder
EP1838296B1 (de) 2004-10-20 2012-08-08 Resverlogix Corp. Flavonoide und isoflavonoide zur vorbeugung und behandlung cardiovasculärer erkrankungen
EP1804785A2 (de) 2004-10-27 2007-07-11 Neurogen Corporation Diaryl-harnstoffe als cb1-antagonisten
US7563785B2 (en) 2004-10-29 2009-07-21 Hypnion, Inc. Quetiapine analogs and methods of use thereof
SA05260357B1 (ar) 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
GB0426313D0 (en) 2004-12-01 2005-01-05 Merck Sharp & Dohme Therapeutic agents
AR051978A1 (es) 2004-12-01 2007-02-21 Divergence Inc Composiciones plaguicidas y metodos
US20080015223A1 (en) 2004-12-03 2008-01-17 Arena Pharmaceuticals, Inc. Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto
EP1831172B1 (de) 2004-12-28 2009-02-18 Council of Scientific and Industrial Research Substituierte carbaminsäurechinolin-6-ylester, die sich als acetylchinolylesteraseinhibitoren eignen
ES2465469T3 (es) 2005-01-14 2014-06-05 Gilead Connecticut, Inc. Diaril ureas 1,3-sustituidas como moduladores de la actividad quinasa
US20080200530A1 (en) 2005-01-19 2008-08-21 Unett David J Diaryl and Arylheteroaryl Urea Derivatives as Modulators of 5-Ht2a Serotonin Receptor Useful for the Prophylaxis or Treatment of Progressive Multifocal Leukoencephalopathy
EP1734039A1 (de) 2005-06-13 2006-12-20 Esbatech AG Arylharnstoffverbindungen als BETA-Secretase-Hemmer
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
KR20080055963A (ko) 2005-09-29 2008-06-19 아레나 파마슈티칼스, 인크. 5-ht2a 세로토닌 수용체 조절제와 관련된 장애의 치료에유용한 5-ht2a 세로토닌 수용체 조절제의 제약 조성물
ES2536762T3 (es) 2006-05-18 2015-05-28 Arena Pharmaceuticals, Inc. Aminas primarias y sus derivados como moduladores del receptor de la serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con este
CN104761498B (zh) 2006-05-18 2017-12-26 艾尼纳制药公司 5‑ht2a血清素受体的调节剂

Also Published As

Publication number Publication date
CA2559038C (en) 2013-09-10
EP1727803A1 (de) 2006-12-06
EP1727803B1 (de) 2012-03-07
CN1926114B (zh) 2011-08-24
WO2005103011A1 (en) 2005-11-03
HK1092152A1 (en) 2007-02-02
US7812176B2 (en) 2010-10-12
US20070293685A1 (en) 2007-12-20
CN1926114A (zh) 2007-03-07
EP1727803B3 (de) 2014-04-23
CA2559038A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
ATE548353T1 (de) Verfahren zur herstellung von substituierte n- aryl-n'-ä3-(1h-pyrazol-5-yl)phenylü-harnstoffe and intermediate davon.
EA200701588A1 (ru) Способы получения замещённых фенилпиразолмочевин
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
DE602006021645D1 (de) Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
SE0303180D0 (sv) Novel compounds
ATE520656T1 (de) Verfahren zur herstellung von 2-oxo-1- pyrrolidinderivaten
TW200801013A (en) Substituted benzofused derivatives and their use as vanilloid receptor ligands
EA200601141A1 (ru) Сульфонамидные производные для лечения заболеваний
ATE478084T1 (de) Verfahren zur herstellung von 4'- azidocytidinderivaten
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
DE60133817D1 (de) Verfahren zur herstellung von aplidin und neue antitumoralen derivate, verfahren zu deren herstellung und zu deren verwendung
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
EA200801302A1 (ru) Композиции и способы лечения нарушений цнс
ATE447567T1 (de) Verfahren zur herstellung von tryptase- inhibitoren
EA200870606A1 (ru) Серосодержащие производные пиразола в качестве избирательных антагонистов рецептора каннабиноидов св
ATE446299T1 (de) Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin
ATE354583T1 (de) Verfahren zur herstellung c-7 substituierter 5- androstene
DE602007008691D1 (de) Cyclische sulfone, die zur verwendung als bace-inhibitoren geeignet sind
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
DE602004021358D1 (de) Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
ATE372114T1 (de) Verfahren zur erhöhung des testosteronspiegels
ATE519755T1 (de) Modulatoren des vitamin-d-rezeptors
ATE449077T1 (de) Benzimidazolderivate und ihre verwendung zur modulierung des gabaa-rezeptorkomplexes
ATE397611T1 (de) Verfahren zur herstellung von olanzapin